The company expects total revenues in the fourth quarter of 2022 to be in the range of $853 million to $868 million. COVID-19 product revenue is expected to be in the range of $124 million to $134 million and non-COVID-19 product revenue is expected to be in the range of $729 million to $734 million, representing 485% growth on a GAAP basis and 18% growth on a proforma constant currency basis at the midpoint.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QDEL:
- Billionaire David Rubenstein Says Recession Is Likely, but Stays Heavily Invested in These 2 Stocks
- Quidel TriageTrue hsTnl Test approved by Health Canada
- QuidelOrtho, Runda Medical form JV to develop assays for VITROS Platform
- QuidelOrtho management to meet with Craig-Hallum
- QuidelOrtho provides three-year outlook at investor day
